Comparative Pharmacology
Head-to-head clinical analysis: GLYCOPYRRONIUM TOSYLATE versus HICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLYCOPYRRONIUM TOSYLATE versus HICON.
GLYCOPYRRONIUM TOSYLATE vs HICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3), inhibiting parasympathetic nerve impulses. Blocks the action of acetylcholine at autonomic effector sites innervated by postganglionic cholinergic nerves, reducing salivary, bronchial, and gastric secretions, and relaxing smooth muscle.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
Glycopyrronium tosylate: 1-2 mg orally 2-3 times daily; maximum 8 mg daily.
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
None Documented
None Documented
Terminal elimination half-life: 0.6–1.2 hours in adults with normal renal function; prolonged in renal impairment (up to 3–4 hours). Clinically, duration of action is longer than half-life due to high receptor affinity.
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Renal: 85% unchanged; biliary/fecal: ~5% as metabolites and unchanged drug; elimination primarily via glomerular filtration and tubular secretion.
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Category C
Category C
Anticholinergic
Anticholinergic